Vaxxinity Inc
OTC:VAXX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Vaxxinity Inc
OTC:VAXX
|
US |
|
Gaotu Techedu Inc
NYSE:GOTU
|
CN |
|
Advanced Enzyme Technologies Ltd
NSE:ADVENZYMES
|
IN |
|
Shenyang Huitian Thermal Power Co Ltd
SZSE:000692
|
CN |
|
T
|
Trial Holdings Inc
TSE:141A
|
JP |
|
T
|
Technical Olympic SA
ATHEX:OLYMP
|
GR |
|
S
|
Square Enix Holdings Co Ltd
TSE:9684
|
JP |
|
EHang Holdings Ltd
NASDAQ:EH
|
CN |
|
B
|
Broadex Technologies Co Ltd
SZSE:300548
|
CN |
|
Software AG
XETRA:SOW
|
DE |
|
Energiekontor AG
XETRA:EKT
|
DE |
|
Maisons du Monde SA
PAR:MDM
|
FR |
|
E
|
Engine Gaming and Media Inc
NASDAQ:GAME
|
CA |
|
G
|
Garda Diversified Property Fund
ASX:GDF
|
AU |
|
B
|
BVZ Holding AG
LSE:0QML
|
CH |
|
Kinepolis Group NV
F:KPSN
|
BE |
|
Nettlinx Ltd
BSE:511658
|
IN |
Vaxxinity Inc
Vaxxinity, Inc. is a biotechnology company that aims to democratize health by bringing the efficiency of vaccines to chronic diseases. The company is headquartered in Dallas, Texas and currently employs 89 full-time employees. The company went IPO on 2021-11-11. The Company’s synthetic peptide vaccine platform (Vaxxine Platform) enables a new class of therapeutics that will improve the access to treatments for a range of indications. Its Vaxxine Platform is designed to connect the immune system to convert the body into its own drug factory, stimulating the production of antibodies with a therapeutic or protective effect. Its technology uses synthetic peptides to mimic and optimally combine biological epitopes in order to selectively activate the immune system, producing antibodies against only the desired targets, including self-antigens, making possible the safe and effective treatment of chronic diseases by vaccines. The modular and synthetic nature of its Vaxxine Platform provides significant in candidate development and has generated multiple product candidates that it is designing for many chronic diseases.
Vaxxinity, Inc. is a biotechnology company that aims to democratize health by bringing the efficiency of vaccines to chronic diseases. The company is headquartered in Dallas, Texas and currently employs 89 full-time employees. The company went IPO on 2021-11-11. The Company’s synthetic peptide vaccine platform (Vaxxine Platform) enables a new class of therapeutics that will improve the access to treatments for a range of indications. Its Vaxxine Platform is designed to connect the immune system to convert the body into its own drug factory, stimulating the production of antibodies with a therapeutic or protective effect. Its technology uses synthetic peptides to mimic and optimally combine biological epitopes in order to selectively activate the immune system, producing antibodies against only the desired targets, including self-antigens, making possible the safe and effective treatment of chronic diseases by vaccines. The modular and synthetic nature of its Vaxxine Platform provides significant in candidate development and has generated multiple product candidates that it is designing for many chronic diseases.
